. "16 hours (also reported at 22-28 hours)"@en . . . "For the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis. Also for the treatment of onchocerciasis (river blindness) due to the nematode parasite Onchocerca volvulus. Can be used to treat scabies caused by Sarcoptes scabiei."@en . "When administered with a high fat meal, the bioavailability is increased 2.5 times."@en . "Parasitic nematodes and other roundworms"@en . . "Ivermectine"@en . . "The volume of distribution is 3 to 3.5 L/kg and it does not cross the blood-brain barrier."@en . . . . . "Ivermectin is a broad-spectrum anti-parasite medication. It was first marketed under the name Stromectol\u00AE and used against worms (except tapeworms), but, in 2012, it was approved for the topical treatment of head lice infestations in patients 6 months of age and older, and marketed under the name Sklice\u2122 as well. Ivermectin is mainly used in humans in the treatment of onchocerciasis, but is also effective against other worm infestations (such as strongyloidiasis, ascariasis, trichuriasis and enterobiasis)."@en . . "Ivermectin is metabolized in the liver, and ivermectin and/or its metabolites are excreted almost exclusively in the feces over an estimated 12 days, with less than 1% of the administered dose excreted in the urine."@en . . "approved"@en . . . . . . . . . . . . " "@en . "70288-86-7"@en . . . . . "93%"@en . "Ivermectin"@en . . . "Shuet-Hing L. Chiu, Josephine R. Carlin, Rae Taub, \"Ivermectin derivative compounds and process for preparing the same.\" U.S. Patent US4963667, issued June, 1982."@en . . . "Moderately well absorbed. Improved absorption with high fat meal."@en . "Ivermectinum"@en . . . "Head lice"@en . . "Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate muscle and nerve cells of the microfilaria. This binding causes an increase in the permeability of the cell membrane to chloride ions and results in hyperpolarization of the cell, leading to paralysis and death of the parasite. Ivermectin also is believed to act as an agonist of the neurotransmitter gamma-aminobutyric acid (GABA), thereby disrupting GABA-mediated central nervous system (CNS) neurosynaptic transmission. Ivermectin may also impair normal intrauterine development of O. volvulus microfilariae and may inhibit their release from the uteri of gravid female worms."@en . . . . . . . . "LD₅₀ = 29.5 mg/kg (Mouse, oral). LD₅₀ = 10 mg/kg (Rat, oral). Adverse effects include muscle or joint pain, dizziness, fever, headache, skin rash, fast heartbeat."@en . . . . . . . . . . "Ivermectin"@en . . . . . . . . "Ivermectina"@en . . .